Medical/Pharmaceuticals
STA To Market Sarcoma Drug In Australia, New Zealand And SE Asia Following License Deal
SINGAPORE and MELBOURNE, Australia, Oct. 14, 2019 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia (STA) has signed a new license deal, enabling it to provide a global advanced sarcoma therapy to patients inAustralia, New Zealand and throughout SE Asia. Under the ...
2019-10-14 14:00
1340
Kangpu Biopharmaceuticals Successfully Completed Phase I Study of Novel CRL4-CRBN Modulator KPG-818 in the U.S.
SHANGHAI, Oct. 11, 2019 /PRNewswire/ -- Kangpu Biopharmaceuticals announced today that it has successfully completed a first-in-human phase I single ascending dose (SAD) clinical study of KPG-818 conducted inthe United States. This randomized, double-blind, placebo-controlled study evaluated the...
2019-10-11 13:00
1481
WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules
SHANGHAI and CAMBRIDGE, Massachusetts and SANKT AUGUSTIN, Germany, Oct. 10, 2019 /PRNewswire/ -- WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds, GalaXi® offers a...
2019-10-11 08:02
7868
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5
SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced that its I...
2019-10-04 13:40
1428
Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine
QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...
2019-10-03 06:30
1501
Mayne Pharma Signs 20-Year Exclusive License and Supply Agreement for Novel Oral Contraceptive in the US
ADELAIDE, Australia, Oct. 2, 2019 * Mayne Pharma Group Limited (Mayne Pharma or Company) (ASX: MYX) has signed a 20‑year exclusive supply and license agreement with Mithra Pharmaceuticals, SA (Mithra) to commercialise a novel oral contraceptive comprising Estetrol (E4), and drospirenone, (E4/...
2019-10-02 12:01
8782
Shanghai Pharma Global Standard Stock Incentive Scheme to Push Innovation Refiled for Approval
SHANGHAI, Sept. 30, 2019 /PRNewswire/ -- Shanghai Pharmaceuticals Holding Co., Ltd. (Shanghai Pharma) (Hong Kong Stock Exchange: 2607) (Shanghai Stock Exchange: 601607) has launched a new stock incentive plan (the Plan) aligned with international standards aimed at retaining and attracting talent...
2019-10-01 04:00
8364
Ascletis Announces Departure of Chief Financial Officer
HANGZHOU and SHAOXING, China, Sept. 30, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces that Dr.Lindi Tan, Chi...
2019-09-30 16:30
1483
Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 (an Oral EP4 Antagonist) for Locally Advanced Rectal Cancer at ESMO 2019
NORTH BRUNSWICK, New Jersey, Sept. 30, 2019 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye" or "the Company"), a global clinical-stage biopharmaceutical company dedicated to discovery, development and commercialization of new and effective drugs with a focus on Oncology, announced today at the ...
2019-09-30 13:41
1065
The 10th China (Taizhou) International Medical Expo successfully ended
NANJING, China, Sept. 30, 2019 /PRNewswire/ -- From September 18 to 20, the 10th
China (Taizhou) International Medical Expo was held in China Medical City
(CMS), according toChina (Taizhou) Medical Expo News Center.
2019-09-30 13:27
1202
Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019
* The study results presented at the ERS 2019 as a late breaking abstract demonstrated positive safety and tolerance in healthy volunteers * Data demonstrated LPA inhibition of BBT-877 up to 90% in multiple-ascending dose cohorts SEONGNAM, South Korea and MADRID, Sept. 29, 2019 /PRNewswire/ --...
2019-09-30 06:00
1597
Kinoxis Therapeutics Awarded NIH HEAL Initiative Grant to Advance KNX100 for the Treatment of Opioid Withdrawal
MELBOURNE, Australia and SYDNEY, Sept. 29, 2019 /PRNewswire/ -- Kinoxis Therapeutics Pty Ltd, a pre-clinical stage biotechnology company developing novel therapies for substance use disorders and other central nervous system disorders, has been awarded a major grant from the US National Institut...
2019-09-30 05:00
1085
CYZone announced "The 2019 Top 50 Healthcare Innovation Enterprises" in China
HANGZHOU, China, Sept. 26, 2019 /PRNewswire/ -- CYZone (www.cyzone.cn
2019-09-26 21:36
1229
Preclincal Results of Baoyuan's Next-Generation ROS1/NTRK Inhibitor AB-106 Published in Nature Communications
HANGZHOU, China, Sept. 25, 2019 /PRNewswire/ -- The preclinical results of AB-106 (original code: DS-6051b), an investigational next generation ROS1/NTRK dual inhibitor exclusively in-licensed by AnHeart Therapeutics, a wholly-owned subsidiary of Baoyuan Biopharmaceuticals Technology (Hangzhou) C...
2019-09-25 18:35
2437
China Biologic Forms Special Committee to Review "Going Private" Proposal
BEIJING, Sept. 24, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that its board of directors (the "Board") has formed a special committee (th...
2019-09-24 20:00
12337
I-Mab Biopharma Announces Clinical Collaboration to Evaluate TJC4 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Multiple Cancer Types
SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, today annou...
2019-09-23 19:00
1786
CARsgen Announces Investigational CAR-T Therapy CT053 Granted PRIME Eligibility by the European Medicines Agency
SHANGHAI, Sept. 23, 2019 /PRNewswire/ -- CARsgen Therapeutics Inc., a clinical-stage biopharmaceutical company today announced the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) eligibility to its investigational CAR-T cell therapy fully human anti-BCMA (B Cell Maturation ...
2019-09-23 18:00
6119
More Than 9 in 10 Surgeons Encounter a Needlestick Injury, New Global Survey Finds
LONDON, Sept. 20, 2019 /PRNewswire/ -- * 81% believe high quality gloves impact patient outcomes; * 92% agreed high quality gloves improve safety of clinicians; * Survey demonstrates importance surgeons place on high quality gloves in protecting against infection and patient safety; * F...
2019-09-20 07:00
1571
Chipscreen Biosciences's Oringinal New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted
SHENZHEN, China, Sept. 19, 2019 /PRNewswire/ -- The new drug application (NDA) of Chiglitazar (Bilessglu®), an innovative new chemical entity (Category 1 c hemical drug) for type 2 diabetes discovered and developed by Shenzhen Chipscreen Biosciences (Stock Symbol: 688321.SH), has been accepted by ...
2019-09-19 23:02
2334
WuXi Diagnostics to open its first research facility in the U.S.
ROCHESTER, Minn., Sept. 19, 2019 /PRNewswire/ -- WuXi Diagnostics announced today the plan to open its first U.S.-based research and diagnostic testing development facility inRochester, Minnesota to accelerate esoteric diagnostic product development, and bring more personalized and accurate clini...
2019-09-19 20:00
2516
Week's Top Stories
Most Reposted
Agoda and TPB Philippines join hands to bring the world to the Philippines' shores
[Picked up by 339 media titles]
2024-09-18 11:30
Singapore-based video streaming provider teams up with renowned celebrity platform to provide much-needed boost for brands
[Picked up by 326 media titles]
2024-09-13 17:12
FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
[Picked up by 315 media titles]
2024-09-16 11:50
NATIONAL ENERGY AWARDS 2024 SHOWCASES MALAYSIA'S COMMITMENT TO ENERGY MANAGEMENT, ENERGY EFFICIENCY AND RENEWABLE ENERGY SOLUTIONS
[Picked up by 289 media titles]
2024-09-13 15:00
Mox Capital Announces Strategic Support for Rapid-Scaling Startups Across Vietnam and Southeast Asia
[Picked up by 284 media titles]
2024-09-14 17:37
Most Read
NATIONAL ENERGY AWARDS 2024 SHOWCASES MALAYSIA'S COMMITMENT TO ENERGY MANAGEMENT, ENERGY EFFICIENCY AND RENEWABLE ENERGY SOLUTIONS
2024-09-13 15:00
12178
Singapore-based video streaming provider teams up with renowned celebrity platform to provide much-needed boost for brands
2024-09-13 17:12
12102
DITO Shares Experience and Future Strategy on 5G SA Core Network Construction
2024-09-13 11:00
8448
MELISHA LIN CROWNED MISS GRAND MALAYSIA 2024
2024-09-13 17:20
8142
